Moreover, we found that the cumulative in-hospital mortality was significantly higher in patients with simultaneous increase of both hs-cTnI and NT-proBNP than inpatients with an increase of one of these indicator, suggesting that the combination of these two cardiac injury indicators would be more valuable than hs-cTnI alone in defining the presence of ACI and determining the prognosis of COVID-19 patients. The gene discussed is TNNI3; the disease is COVID-19.